A. N. Stetsyuk
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
A. N. Stetsyuk has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Aida Gilyadova
Department of Oncology, Radiotherapy and Reconstructive Surgery, Levshin Institute of Cluster Oncology, Sechenov First Moscow State Medical University, 119435 Moscow, Russia
2 shared publications - Anna Alyasova
Department of Oncology, Radiotherapy and Reconstructive Surgery, Levshin Institute of Cluster Oncology, Sechenov First Moscow State Medical University, 119435 Moscow, Russia
2 shared publications - Dinara Ilyasova
Department of Oncology, Radiotherapy and Reconstructive Surgery, Levshin Institute of Cluster Oncology, Sechenov First Moscow State Medical University, 119435 Moscow, Russia
2 shared publications - Ekaterina Rostislavova
Department of Oncology, Radiotherapy and Reconstructive Surgery, Levshin Institute of Cluster Oncology, Sechenov First Moscow State Medical University, 119435 Moscow, Russia
2 shared publications - Igor Reshetov
Department of Oncology, Radiotherapy and Reconstructive Surgery, N.V. Sklifosovsky Institute of Clinical Medicine, Sechenov First Moscow State Medical University (Sechenov University), Moscow 119991, Russia
2 shared publications - Kanamat Efendiev
Department of Medical Photonics, Prokhorov General Physics Institute of the Russian Academy of Sciences, 119991 Moscow, Russia
2 shared publications
Latest Publications
- Open Access
- 24 July 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (15) , 6623
Current Approaches and Emerging Strategies in the Treatment of Peritoneal Carcinomatosis
Peritoneal carcinomatosis (PC) is a common, prognostically unfavorable manifestation of advanced gastrointestinal and gynecological malignancies whose treatment is constrained by the blood-peritoneal barrier, which limits drug penetration even when cytoreductive surgery is combined with systemic chemotherapy. This review evaluates current intraperitoneal treatment modalities and emerging technologies for overcoming this limitation, based on recent clinical trials and meta-analyses identified through Scopus and PubMed. We sequentially examine conventional intraperitoneal chemotherapy (IPC); hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian, gastric, and colorectal cancers, with attention to patient selection and the peritoneal cancer index as determinants of survival benefit; pressurized intraperitoneal aerosol chemotherapy (PIPAC) and its electrostatic precipitation variant (ePIPAC); and photodynamic and photothermal therapy for tumor treatment. Novel strategies are also discussed, including IPC combined with immune checkpoint inhibitors, optical dosimetry, and nanomedicine-based drug delivery as tools for improving treatment precision. Overall, management of PC is transitioning toward a personalized, multimodal approach: HIPEC and PIPAC provide standardized platforms for regional therapy, but future progress depends on integrating advanced drug delivery systems, immunotherapy, and real-time intraoperative monitoring, with standardization of protocols through large multicenter trials remaining a priority for translating these modalities into clinical practice.
- 24 July 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (15) , 6623
Open AccessCurrent Approaches and Emerging Strategies in the Treatment of Peritoneal Carcinomatosis
Peritoneal carcinomatosis (PC) is a common, prognostically unfavorable manifestation of advanced gastrointestinal and gynecological malignancies whose treatment is constrained by the blood-peritoneal barrier, which limits drug penetration even when cytoreductive surgery is combined with systemic chemotherapy. This review evaluates current intraperitoneal treatment modalities and emerging technologies for overcoming this limitation, based on recent clinical trials and meta-analyses identified through Scopus and PubMed. We sequentially examine conventional intraperitoneal chemotherapy (IPC); hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian, gastric, and colorectal cancers, with attention to patient selection and the peritoneal cancer index as determinants of survival benefit; pressurized intraperitoneal aerosol chemotherapy (PIPAC) and its electrostatic precipitation variant (ePIPAC); and photodynamic and photothermal therapy for tumor treatment. Novel strategies are also discussed, including IPC combined with immune checkpoint inhibitors, optical dosimetry, and nanomedicine-based drug delivery as tools for improving treatment precision. Overall, management of PC is transitioning toward a personalized, multimodal approach: HIPEC and PIPAC provide standardized platforms for regional therapy, but future progress depends on integrating advanced drug delivery systems, immunotherapy, and real-time intraoperative monitoring, with standardization of protocols through large multicenter trials remaining a priority for translating these modalities into clinical practice.
- Open Access
Photodynamic Therapy Combined with Anticancer Drug Therapy in the Treatment of Malignant Neoplasms
Background: Photodynamic therapy (PDT) has emerged as a powerful minimally invasive modality for cancer treatment. However, its efficacy as a monotherapy is often limited by oxygen dependence and limited light penetration. Combining PDT with systemic anticancer drug therapies offers a promising strategy to achieve synergistic effects and overcome resistance. Objective: This review aims to provide a systematic analysis of the mechanisms and clinical potential of combining PDT with chemotherapy, targeted therapy, and immunotherapy, focusing on recent advancements and nanotechnology-based delivery systems. Methods: A comprehensive literature search was performed using PubMed and Scopus databases. The analysis focused on peer-reviewed studies published over the last 10 years addressing synergistic molecular pathways, co-delivery nanoplatforms, and clinical trial outcomes. Results: The combination of PDT with chemotherapy enhances drug accumulation via vascular photosensitization and can overcome multi-drug resistance. Integration with immunotherapy, particularly immune checkpoint inhibitors and tumor vaccines, triggers immunogenic cell death (ICD), leading to systemic antitumor responses. Nanotechnology provides a versatile platform for the targeted co-delivery of photosensitizers and pharmacological agents, significantly reducing systemic toxicity. Conclusions: Combined PDT–drug regimens demonstrate superior therapeutic efficacy compared to monotherapies. Future clinical translation requires the standardization of dosimetry and the development of multifunctional nanomedicines to enable personalized treatment protocols.
Open AccessPhotodynamic Therapy Combined with Anticancer Drug Therapy in the Treatment of Malignant Neoplasms
Background: Photodynamic therapy (PDT) has emerged as a powerful minimally invasive modality for cancer treatment. However, its efficacy as a monotherapy is often limited by oxygen dependence and limited light penetration. Combining PDT with systemic anticancer drug therapies offers a promising strategy to achieve synergistic effects and overcome resistance. Objective: This review aims to provide a systematic analysis of the mechanisms and clinical potential of combining PDT with chemotherapy, targeted therapy, and immunotherapy, focusing on recent advancements and nanotechnology-based delivery systems. Methods: A comprehensive literature search was performed using PubMed and Scopus databases. The analysis focused on peer-reviewed studies published over the last 10 years addressing synergistic molecular pathways, co-delivery nanoplatforms, and clinical trial outcomes. Results: The combination of PDT with chemotherapy enhances drug accumulation via vascular photosensitization and can overcome multi-drug resistance. Integration with immunotherapy, particularly immune checkpoint inhibitors and tumor vaccines, triggers immunogenic cell death (ICD), leading to systemic antitumor responses. Nanotechnology provides a versatile platform for the targeted co-delivery of photosensitizers and pharmacological agents, significantly reducing systemic toxicity. Conclusions: Combined PDT–drug regimens demonstrate superior therapeutic efficacy compared to monotherapies. Future clinical translation requires the standardization of dosimetry and the development of multifunctional nanomedicines to enable personalized treatment protocols.
- Open Access
- 30 November 2025
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 35 (5) , 100-111
A Case Series of Prostate Cancer Metastases to the Sigmoid Mesocolon in Patients with Colorectal Cancer
This article presents three rare clinical cases of prostate cancer metastasis to the mesosigmoid lymph nodes in patients with primary multiple prostate and sigmoid colon cancer. We were able to find descriptions of only three similar cases in international literature. In all cases, the source of metastasis was confirmed by immunohistochemistry: expression of prostate biomarkers and the absence of expression of intestinal adenocarcinoma markers were detected. Furthermore, we describe a case of the so-called “collision phenomenon” in one of the lymph nodes. The detection of prostate cancer metastases to the mesocolic region demonstrates the interconnection between the lymphatic collectors of the colon and the prostate gland. Therefore, it is important to conduct a thorough pathological examination of the surgical specimen, and in ambiguous cases, immunohistochemistry is indicated for accurate diagnosis and treatment planning. Further studies are needed to investigate the relationship between lymphatic drainage pathways from the prostate and distal colon.
- 30 November 2025
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 35 (5) , 100-111
Open AccessA Case Series of Prostate Cancer Metastases to the Sigmoid Mesocolon in Patients with Colorectal Cancer
This article presents three rare clinical cases of prostate cancer metastasis to the mesosigmoid lymph nodes in patients with primary multiple prostate and sigmoid colon cancer. We were able to find descriptions of only three similar cases in international literature. In all cases, the source of metastasis was confirmed by immunohistochemistry: expression of prostate biomarkers and the absence of expression of intestinal adenocarcinoma markers were detected. Furthermore, we describe a case of the so-called “collision phenomenon” in one of the lymph nodes. The detection of prostate cancer metastases to the mesocolic region demonstrates the interconnection between the lymphatic collectors of the colon and the prostate gland. Therefore, it is important to conduct a thorough pathological examination of the surgical specimen, and in ambiguous cases, immunohistochemistry is indicated for accurate diagnosis and treatment planning. Further studies are needed to investigate the relationship between lymphatic drainage pathways from the prostate and distal colon.